Beyond chemoradiotherapy: improving treatment outcomes for patients with stage III unresectable non-small-cell lung cancer through immuno-oncology and durvalumab (Imfinzi®▼ AstraZeneca UK Limited)

摘要

Shown are Kaplan–Meier curves for updated PFS, defined according to the RECIST v1.1, and assessed by blinded-independent central review. Tick marks indicate censored observations, and vertical dotted lines indicate the times of landmark PFS analyses. The intention-to-treat population included all patients who underwent randomisation. Data cut-off for updated PFS was March 22, 2018, and median follow-up was 25.2 months. *No formal statistical comparison was made at this analysis for PFS because the study had achieved significance for PFS at the first planned interim analysis (data cut-off of Feb 13, 2017).30 Adapted from Antonia et al.30 Reprinted with permission from Massachusetts Medical Society.